{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:29:44Z","timestamp":1782962984672,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["33CM30-124112"],"award-info":[{"award-number":["33CM30-124112"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SPUM33C30-140336"],"award-info":[{"award-number":["SPUM33C30-140336"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.atherosclerosis.2018.06.871","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T13:52:58Z","timestamp":1529675578000},"page":"368-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Lipid management in ACS: Should we go lower faster?"],"prefix":"10.1016","volume":"275","author":[{"given":"Baris","family":"Gencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib2","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/eurheartj\/ehv056","article-title":"Sweetless'n low LDL-C targets for PCSK9 treatment","volume":"36","author":"Gencer","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"Jama"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2018.06.871_bib6","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials","volume":"39","author":"Koskinas","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib7","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2018.06.871_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.2018.2444","article-title":"Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial","volume":"319","author":"Berwanger","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.atherosclerosis.2014.12.049","article-title":"Expected impact of applying new 2013 AHA\/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes","volume":"239","author":"Gencer","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib12","first-page":"2473","article-title":"Comprehensive efforts to increase adherence to statin therapy","volume":"38","author":"Vonbank","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2016.07.140","article-title":"Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus","volume":"222","author":"Liu","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib14","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the improve-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the improve-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.06.871_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs. Without diabetes: results from improve-IT","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib20","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib21","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib24","first-page":"39","article-title":"No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials meta-analysis of individual participant data","author":"Harvey","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib29","article-title":"Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"2017","author":"Landmesser","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib30","first-page":"6","article-title":"Eligibility for PCSK9 inhibitors according to american College of Cardiology (ACC) and european society of cardiology\/european Atherosclerosis society (ESC\/EAS) guidelines after acute coronary syndromes","author":"Gencer","year":"2017","journal-title":"J\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib31","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2018.06.871_bib34","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOL.0000000000000311","article-title":"Identifying familial hypercholesterolemia in acute coronary syndrome","volume":"27","author":"Gencer","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2018.06.871_bib36","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2018.2426","article-title":"Lipid lowering in acute coronary syndrome: is treatment early enough?","volume":"319","author":"Nicholls","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2018.06.871_bib37","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018311833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018311833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:37:32Z","timestamp":1758155852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018311833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"alternative-id":["S0021915018311833"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.871","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid management in ACS: Should we go lower faster?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}